These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Carrier screening for cystic fibrosis. Dungan JS Obstet Gynecol Clin North Am; 2010 Mar; 37(1):47-59, Table of Contents. PubMed ID: 20494257 [TBL] [Abstract][Full Text] [Related]
3. Community-wide screening for cystic fibrosis carriers could replace newborn screening for the diagnosis of cystic fibrosis. Wilcken B J Paediatr Child Health; 2008 Apr; 44(4):232-3; author reply 233. PubMed ID: 18377372 [No Abstract] [Full Text] [Related]
4. Cystic fibrosis screening at the Greenville Hospital System. Dacus J; Mabie B; Gailey T; Rogers C; Likes C; Metcalf L J S C Med Assoc; 2006 Feb; 102(1):14-6. PubMed ID: 16704181 [TBL] [Abstract][Full Text] [Related]
5. Association between carrier screening and incidence of cystic fibrosis. Castellani C; Picci L; Tamanini A; Girardi P; Rizzotti P; Assael BM JAMA; 2009 Dec; 302(23):2573-9. PubMed ID: 20009057 [TBL] [Abstract][Full Text] [Related]
6. Community-wide screening for cystic fibrosis carriers could replace newborn screening for the diagnosis of cystic fibrosis. Massie J; Forbes R; Dusart D; Bankier A; Delatycki MB J Paediatr Child Health; 2007 Nov; 43(11):721-3. PubMed ID: 17924936 [TBL] [Abstract][Full Text] [Related]
7. [Conditions and limitations of healthy carrier screening for the mutation responsible for cystic fibrosis]. Serre JL; Feingold J Rev Epidemiol Sante Publique; 1993; 41(5):353-62. PubMed ID: 8284475 [TBL] [Abstract][Full Text] [Related]
8. Impact of public health strategies on the birth prevalence of cystic fibrosis in Brittany, France. Scotet V; Audrézet MP; Roussey M; Rault G; Blayau M; De Braekeleer M; Férec C Hum Genet; 2003 Aug; 113(3):280-5. PubMed ID: 12768409 [TBL] [Abstract][Full Text] [Related]
12. Neonatal screening for cystic fibrosis in the Trent region (UK): two-stage immunoreactive trypsin screening compared with a three-stage protocol with DNA analysis as an intermediate step. Pollitt RJ; Dalton A; Evans S; Hughes HN; Curtis D J Med Screen; 1997; 4(1):23-8. PubMed ID: 9200059 [TBL] [Abstract][Full Text] [Related]
13. [A new strategy of neonatal screening for cystic fibrosis. The association of immunoreactive trypsin and molecular biology in dried blood]. Laroche D; Peres O; Briard ML; Lemonnier F; Pasquet-Ferre C; Blandin C; Travert G; Fernandez Y Arch Fr Pediatr; 1990 Apr; 47(4):251-3. PubMed ID: 2363611 [TBL] [Abstract][Full Text] [Related]
14. An evaluation of population screening for carriers of cystic fibrosis. Smith MJ J Public Health Med; 1992 Sep; 14(3):257-63. PubMed ID: 1419203 [No Abstract] [Full Text] [Related]
18. [Mucoviscidosis screening by determination of immunoreactive trypsin]. Sander J; Niehaus C Klin Padiatr; 1984; 196(4):224-7. PubMed ID: 6482307 [TBL] [Abstract][Full Text] [Related]
19. Newborn screening for cystic fibrosis in Wisconsin: first application of population-based molecular genetics testing. Farrell PM; Aronson RA; Hoffman G; Laessig RH Wis Med J; 1994 Aug; 93(8):415-21. PubMed ID: 7975706 [TBL] [Abstract][Full Text] [Related]
20. Screening for cystic fibrosis in newborn infants: results of a pilot programme based on a two tier protocol (IRT/DNA/IRT) in the Italian population. Corbetta C; Seia M; Bassotti A; Ambrosioni A; Giunta A; Padoan R J Med Screen; 2002; 9(2):60-3. PubMed ID: 12133923 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]